MSB 7.69% $1.19 mesoblast limited

Ryoncil: ODAC/FDA Meeting Discussion, page-15

  1. 618 Posts.
    lightbulb Created with Sketch. 20
    Moreover, although there currently is no FDA-approved treatment for pediatric patients
    younger than 12 years old, FDA would actually do such patients a disservice by approving an
    unproven and potentially ineffective treatment based upon an inadequate dataset.

    What a load of garbage eh?
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.